Skip to main content
FDA Approved
Prescription Medicine

Hot Flash Pills

A daily prescription pill (neurokinin receptor antagonist) that blocks NK3 receptors in the brain to reduce hot flashes and night sweats.

Last verified: · Updated:

Method at a Glance

Measured outcomeRecommendedGuideline status: Recommended
DurationDaily pill (ongoing)
Cost$0–$780
/monthly
Used forHot flash & night sweat relief
How you get itTelehealth Prescription
Available Products

2 products in this category

Specific branded items that use this method. Compare manufacturer details, active ingredients, and regulatory status.

The details

What the evidence says

How well it works, what to watch for, who should avoid it, and the studies behind it.

Outcome & guideline status

Recommended

Guideline status: Recommended

This method class covers NK3 antagonists and dual NK1/NK3 antagonists. In Phase 3 trials, fezolinetant 45 mg reduced moderate-to-severe hot flashes and night sweats by 2.53-2.55 episodes per day versus placebo at week 12 (between-group difference in least squares mean change, p<0.001), and elinzanetant 120 mg reduced them by about 3.2 episodes per day versus placebo at week 12 (between-group difference, p<0.001). Responder rates also differ between products, so no single percentage captures the class. NAMS 2023 lists fezolinetant as a Level I recommendation; the FDA approved elinzanetant in October 2025, after the 2023 statement was published, so the statement did not individually evaluate elinzanetant.

Cost & insurance

$0–$780/monthly

Monthly retail prices for neurokinin antagonist products are typically around $700-$780 for fezolinetant and about $740 for elinzanetant; with pharmacy discount coupons the cash price drops to roughly $485-$620 for fezolinetant and $615-$620 for elinzanetant. Actual cost depends on pharmacy, insurance, and manufacturer savings programs.

Insurance CoverageUsually

Duration & reversibility

Lasts forDaily pill (ongoing)
Reversibility
Reversible

The science

Clinical classNeurokinin receptor antagonist
How it works in the body

Blocks neurokinin-3 (NK3) and/or neurokinin-1 (NK1) receptors in the hypothalamus to interrupt the temperature-regulation pathway that triggers hot flashes and night sweats.

Regulatory status & access

StatusFDA Approved
Used forHot flash & night sweat relief
How you get itTelehealth Prescription
PrescriptionRequired

Special monitoring required

Hot Flash Pills requires blood tests (baseline and periodic liver function tests) to monitor safety during use.

Side effects

  • Elevated liver enzymes (requires monitoring)
  • Abdominal pain
  • Diarrhea
  • Insomnia
  • Back pain
  • Hot flush
  • Headache
  • Somnolence, dizziness, and fatigue (more common with dual NK1/NK3 antagonists)

Who shouldn't use this

  • Cirrhosis or severe liver disease (NK3 antagonists such as fezolinetant)(Severe liver damage or reduced liver function)
  • Severe renal impairment or end-stage renal disease (NK3 antagonists such as fezolinetant)(Reduced kidney function or kidney disease)
  • Concomitant use of CYP1A2 inhibitors such as fluvoxamine or ciprofloxacin (NK3 antagonists such as fezolinetant)(Taking medicines like fluvoxamine or ciprofloxacin that affect liver processing)
  • Pregnancy (dual NK1/NK3 antagonists such as elinzanetant)(The treatment is not intended for use during pregnancy and may harm a fetus)

Clinical guidelines

NAMS

2023 Position Statement - Level I recommendation for hot flashes and night sweats

View Guideline
The full picture

What to know about Hot Flash Pills

How it works

Neurokinin receptor antagonists are a new class of non-hormonal prescription pills for menopause hot flashes and night sweats. They block neurokinin receptors in the hypothalamus, the part of the brain that regulates body temperature. By interrupting the pathway that triggers hot flashes, they reduce both the frequency and severity of vasomotor symptoms.

Research and approval status

Two neurokinin receptor antagonists are FDA-approved. The FDA approved fezolinetant, an NK3 antagonist, in 2023, and approved elinzanetant, a dual NK1/NK3 antagonist, in 2025. In SKYLIGHT 1 and SKYLIGHT 2, fezolinetant 45 mg reduced daily hot flash and night sweat frequency by 2.53 to 2.55 episodes per day more than placebo at week 12 (p<0.001). In the OASIS 1 and 2 trials, elinzanetant 120 mg reduced daily frequency by about 3.2 episodes per day more than placebo at week 12. The Menopause Society (NAMS 2023) lists fezolinetant as a Level I recommendation; the FDA approved elinzanetant in October 2025, after the 2023 statement was published.

Side effects and cautions

Fezolinetant carries an FDA boxed warning about the risk of hepatotoxicity (liver injury). Neurokinin antagonists can affect the liver, so you need baseline liver function blood tests before starting one. With NK3 antagonists such as fezolinetant, tests are repeated monthly for the first 3 months, then again at 6 and 9 months. With dual NK1/NK3 antagonists such as elinzanetant, a repeat test at 3 months is recommended. Do not take an NK3 antagonist if you have cirrhosis, severe kidney disease, or take CYP1A2 inhibitors such as fluvoxamine or ciprofloxacin. Dual NK1/NK3 antagonists are contraindicated in pregnancy and not recommended for people with moderate or severe hepatic impairment or end-stage renal disease. Avoid strong CYP3A4 inhibitors (including grapefruit juice) and strong or moderate CYP3A4 inducers; if you take a moderate CYP3A4 inhibitor, reduce the dose to 60 mg (one capsule). Elinzanetant can cause sleepiness and affect your ability to drive or do hazardous activities the next day, and people with a history of seizures should talk to their clinician before using it.

Where to get it

You need a prescription, which you can get through telehealth or a menopause specialist. You take it as a daily pill. Check our provider directory for clinics near you.

The studies

Clinical trials behind Hot Flash Pills

The research that backs Hot Flash Pills, with links to the public trial records.

Phase 3Completed

SKYLIGHT 1 (fezolinetant)

ClinicalTrials.gov: NCT04003155
Phase 3Completed

SKYLIGHT 2 (fezolinetant)

ClinicalTrials.gov: NCT04003142
Phase 3Completed

OASIS 1 (elinzanetant)

ClinicalTrials.gov: NCT05042362
Phase 3Completed

OASIS 2 (elinzanetant)

ClinicalTrials.gov: NCT05099159
Phase 3Completed

OASIS 3 (elinzanetant long-term)

ClinicalTrials.gov: NCT05030584